The Experts below are selected from a list of 306 Experts worldwide ranked by ideXlab platform
Tengfu Hsieh - One of the best experts on this subject based on the ideXlab platform.
-
5-alpha-reductase inhibitor therapy postpones Urine Retention and prostate surgery in patients with prostate enlargement and a maximum uroflow rate of less than 15 ml/sec.
PloS one, 2017Co-Authors: Wenhsu Lin, Yu-hung Kuo, Shang-sen Lee, Tengfu HsiehAbstract:Background This study investigated the risk of transurethral resection of prostate (TURP) and acute Urine Retention (AUR) in relation to 5-alpha-reductase inhibitor (5ARI) therapy. Methods We identified 22,687 patients who were newly diagnosed with PE and low urinary tract symptoms (LUTS) between January 1, 2002 and December 31, 2011. We further classified study subjects who had moderate to severe LUTS and a maximum uroflow rate of less than 15ml/sec into three groups by their defined daily dose (DDD) of 5ARI used. The control group consisted of 7-28 cumulative DDD (cDDD) 5ARI users, while the short-term treatment group was 29-179cDDD 5ARI users, and the long-term treatment group was users of more than 180cDDD 5ARI. Each patient was monitored to identify those who subsequently developed TURP and AUR. Results TURP and AUR are detected in 5.6% of control group, 7.6% of short-term treatment group and 5.5% of long-term treatment group during 10-year follow up. Compared with the control group, there was no difference in the risk of TURP and AUR in the short-term and long-term treatment groups (HR = 1.41, 95% CI 0.76 to 2.62 and HR = 0.81, 95% CI 0.42 to 1.56, respectively). Conclusion 5ARI therapy did not change the risk of TURP and AUR events in patients with PE, moderate to severe LUTS and a maximum uroflow rate of less than 15 ml/sec in 10 years of follow-up. But long-term 5ARI used can postpone AUR and TURP for 8.16 months.
-
maximum Urine flow rate of less than 15ml sec increasing risk of Urine Retention and prostate surgery among patients with alpha 1 blockers a 10 year follow up study
PLOS ONE, 2016Co-Authors: Tsunghsun Tsai, Tengfu HsiehAbstract:Background The aim of this study was to determine the subsequent risk of acute Urine Retention and prostate surgery in patients receiving alpha-1 blockers treatment and having a maximum urinary flow rate of less than 15ml/sec. Methods We identified patients who were diagnosed with benign prostate hyperplasia (BPH) and had a maximum uroflow rate of less than 15ml/sec between 1 January, 2002 to 31 December, 2011 from Taiwan’s National Health Insurance Research Database into study group (n = 303). The control cohort included four BPH/LUTS patients without 5ARI used for each study group, randomly selected from the same dataset (n = 1,212). Each patient was monitored to identify those who subsequently developed prostate surgery and acute Urine Retention. Results Prostate surgery and acute Urine Retention are detected in 5.9% of control group and 8.3% of study group during 10-year follow up. Compared with the control group, there was increase in the risk of prostate surgery and acute Urine Retention in the study group (HR = 1.83, 95% CI: 1.16 to 2.91) after adjusting for age, comorbidities, geographic region and socioeconomic status. Conclusions Maximum Urine flow rate of less than 15ml/sec is a risk factor of urinary Retention and subsequent prostate surgery in BPH patients receiving alpha-1 blocker therapy. This result can provide a reference for clinicians.
-
Maximum Urine Flow Rate of Less than 15ml/Sec Increasing Risk of Urine Retention and Prostate Surgery among Patients with Alpha-1 Blockers: A 10-Year Follow Up Study.
PLOS ONE, 2016Co-Authors: Tsunghsun Tsai, Tengfu HsiehAbstract:Background The aim of this study was to determine the subsequent risk of acute Urine Retention and prostate surgery in patients receiving alpha-1 blockers treatment and having a maximum urinary flow rate of less than 15ml/sec. Methods We identified patients who were diagnosed with benign prostate hyperplasia (BPH) and had a maximum uroflow rate of less than 15ml/sec between 1 January, 2002 to 31 December, 2011 from Taiwan’s National Health Insurance Research Database into study group (n = 303). The control cohort included four BPH/LUTS patients without 5ARI used for each study group, randomly selected from the same dataset (n = 1,212). Each patient was monitored to identify those who subsequently developed prostate surgery and acute Urine Retention. Results Prostate surgery and acute Urine Retention are detected in 5.9% of control group and 8.3% of study group during 10-year follow up. Compared with the control group, there was increase in the risk of prostate surgery and acute Urine Retention in the study group (HR = 1.83, 95% CI: 1.16 to 2.91) after adjusting for age, comorbidities, geographic region and socioeconomic status. Conclusions Maximum Urine flow rate of less than 15ml/sec is a risk factor of urinary Retention and subsequent prostate surgery in BPH patients receiving alpha-1 blocker therapy. This result can provide a reference for clinicians.
-
Maximum Urine Flow Rate of Less than 15ml/Sec Increasing Risk of Urine Retention and Prostate Surgery among Patients with Alpha-1 Blockers: A 10-Year Follow Up Study.
PloS one, 2016Co-Authors: Hsin-ho Liu, Tsunghsun Tsai, Shang-sen Lee, Yu-hung Kuo, Tengfu HsiehAbstract:The aim of this study was to determine the subsequent risk of acute Urine Retention and prostate surgery in patients receiving alpha-1 blockers treatment and having a maximum urinary flow rate of less than 15ml/sec. We identified patients who were diagnosed with benign prostate hyperplasia (BPH) and had a maximum uroflow rate of less than 15ml/sec between 1 January, 2002 to 31 December, 2011 from Taiwan's National Health Insurance Research Database into study group (n = 303). The control cohort included four BPH/LUTS patients without 5ARI used for each study group, randomly selected from the same dataset (n = 1,212). Each patient was monitored to identify those who subsequently developed prostate surgery and acute Urine Retention. Prostate surgery and acute Urine Retention are detected in 5.9% of control group and 8.3% of study group during 10-year follow up. Compared with the control group, there was increase in the risk of prostate surgery and acute Urine Retention in the study group (HR = 1.83, 95% CI: 1.16 to 2.91) after adjusting for age, comorbidities, geographic region and socioeconomic status. Maximum Urine flow rate of less than 15ml/sec is a risk factor of urinary Retention and subsequent prostate surgery in BPH patients receiving alpha-1 blocker therapy. This result can provide a reference for clinicians.
Tsunghsun Tsai - One of the best experts on this subject based on the ideXlab platform.
-
maximum Urine flow rate of less than 15ml sec increasing risk of Urine Retention and prostate surgery among patients with alpha 1 blockers a 10 year follow up study
PLOS ONE, 2016Co-Authors: Tsunghsun Tsai, Tengfu HsiehAbstract:Background The aim of this study was to determine the subsequent risk of acute Urine Retention and prostate surgery in patients receiving alpha-1 blockers treatment and having a maximum urinary flow rate of less than 15ml/sec. Methods We identified patients who were diagnosed with benign prostate hyperplasia (BPH) and had a maximum uroflow rate of less than 15ml/sec between 1 January, 2002 to 31 December, 2011 from Taiwan’s National Health Insurance Research Database into study group (n = 303). The control cohort included four BPH/LUTS patients without 5ARI used for each study group, randomly selected from the same dataset (n = 1,212). Each patient was monitored to identify those who subsequently developed prostate surgery and acute Urine Retention. Results Prostate surgery and acute Urine Retention are detected in 5.9% of control group and 8.3% of study group during 10-year follow up. Compared with the control group, there was increase in the risk of prostate surgery and acute Urine Retention in the study group (HR = 1.83, 95% CI: 1.16 to 2.91) after adjusting for age, comorbidities, geographic region and socioeconomic status. Conclusions Maximum Urine flow rate of less than 15ml/sec is a risk factor of urinary Retention and subsequent prostate surgery in BPH patients receiving alpha-1 blocker therapy. This result can provide a reference for clinicians.
-
Maximum Urine Flow Rate of Less than 15ml/Sec Increasing Risk of Urine Retention and Prostate Surgery among Patients with Alpha-1 Blockers: A 10-Year Follow Up Study.
PLOS ONE, 2016Co-Authors: Tsunghsun Tsai, Tengfu HsiehAbstract:Background The aim of this study was to determine the subsequent risk of acute Urine Retention and prostate surgery in patients receiving alpha-1 blockers treatment and having a maximum urinary flow rate of less than 15ml/sec. Methods We identified patients who were diagnosed with benign prostate hyperplasia (BPH) and had a maximum uroflow rate of less than 15ml/sec between 1 January, 2002 to 31 December, 2011 from Taiwan’s National Health Insurance Research Database into study group (n = 303). The control cohort included four BPH/LUTS patients without 5ARI used for each study group, randomly selected from the same dataset (n = 1,212). Each patient was monitored to identify those who subsequently developed prostate surgery and acute Urine Retention. Results Prostate surgery and acute Urine Retention are detected in 5.9% of control group and 8.3% of study group during 10-year follow up. Compared with the control group, there was increase in the risk of prostate surgery and acute Urine Retention in the study group (HR = 1.83, 95% CI: 1.16 to 2.91) after adjusting for age, comorbidities, geographic region and socioeconomic status. Conclusions Maximum Urine flow rate of less than 15ml/sec is a risk factor of urinary Retention and subsequent prostate surgery in BPH patients receiving alpha-1 blocker therapy. This result can provide a reference for clinicians.
-
Maximum Urine Flow Rate of Less than 15ml/Sec Increasing Risk of Urine Retention and Prostate Surgery among Patients with Alpha-1 Blockers: A 10-Year Follow Up Study.
PloS one, 2016Co-Authors: Hsin-ho Liu, Tsunghsun Tsai, Shang-sen Lee, Yu-hung Kuo, Tengfu HsiehAbstract:The aim of this study was to determine the subsequent risk of acute Urine Retention and prostate surgery in patients receiving alpha-1 blockers treatment and having a maximum urinary flow rate of less than 15ml/sec. We identified patients who were diagnosed with benign prostate hyperplasia (BPH) and had a maximum uroflow rate of less than 15ml/sec between 1 January, 2002 to 31 December, 2011 from Taiwan's National Health Insurance Research Database into study group (n = 303). The control cohort included four BPH/LUTS patients without 5ARI used for each study group, randomly selected from the same dataset (n = 1,212). Each patient was monitored to identify those who subsequently developed prostate surgery and acute Urine Retention. Prostate surgery and acute Urine Retention are detected in 5.9% of control group and 8.3% of study group during 10-year follow up. Compared with the control group, there was increase in the risk of prostate surgery and acute Urine Retention in the study group (HR = 1.83, 95% CI: 1.16 to 2.91) after adjusting for age, comorbidities, geographic region and socioeconomic status. Maximum Urine flow rate of less than 15ml/sec is a risk factor of urinary Retention and subsequent prostate surgery in BPH patients receiving alpha-1 blocker therapy. This result can provide a reference for clinicians.
Shang-sen Lee - One of the best experts on this subject based on the ideXlab platform.
-
5-alpha-reductase inhibitor therapy postpones Urine Retention and prostate surgery in patients with prostate enlargement and a maximum uroflow rate of less than 15 ml/sec.
PloS one, 2017Co-Authors: Wenhsu Lin, Yu-hung Kuo, Shang-sen Lee, Tengfu HsiehAbstract:Background This study investigated the risk of transurethral resection of prostate (TURP) and acute Urine Retention (AUR) in relation to 5-alpha-reductase inhibitor (5ARI) therapy. Methods We identified 22,687 patients who were newly diagnosed with PE and low urinary tract symptoms (LUTS) between January 1, 2002 and December 31, 2011. We further classified study subjects who had moderate to severe LUTS and a maximum uroflow rate of less than 15ml/sec into three groups by their defined daily dose (DDD) of 5ARI used. The control group consisted of 7-28 cumulative DDD (cDDD) 5ARI users, while the short-term treatment group was 29-179cDDD 5ARI users, and the long-term treatment group was users of more than 180cDDD 5ARI. Each patient was monitored to identify those who subsequently developed TURP and AUR. Results TURP and AUR are detected in 5.6% of control group, 7.6% of short-term treatment group and 5.5% of long-term treatment group during 10-year follow up. Compared with the control group, there was no difference in the risk of TURP and AUR in the short-term and long-term treatment groups (HR = 1.41, 95% CI 0.76 to 2.62 and HR = 0.81, 95% CI 0.42 to 1.56, respectively). Conclusion 5ARI therapy did not change the risk of TURP and AUR events in patients with PE, moderate to severe LUTS and a maximum uroflow rate of less than 15 ml/sec in 10 years of follow-up. But long-term 5ARI used can postpone AUR and TURP for 8.16 months.
-
Maximum Urine Flow Rate of Less than 15ml/Sec Increasing Risk of Urine Retention and Prostate Surgery among Patients with Alpha-1 Blockers: A 10-Year Follow Up Study.
PloS one, 2016Co-Authors: Hsin-ho Liu, Tsunghsun Tsai, Shang-sen Lee, Yu-hung Kuo, Tengfu HsiehAbstract:The aim of this study was to determine the subsequent risk of acute Urine Retention and prostate surgery in patients receiving alpha-1 blockers treatment and having a maximum urinary flow rate of less than 15ml/sec. We identified patients who were diagnosed with benign prostate hyperplasia (BPH) and had a maximum uroflow rate of less than 15ml/sec between 1 January, 2002 to 31 December, 2011 from Taiwan's National Health Insurance Research Database into study group (n = 303). The control cohort included four BPH/LUTS patients without 5ARI used for each study group, randomly selected from the same dataset (n = 1,212). Each patient was monitored to identify those who subsequently developed prostate surgery and acute Urine Retention. Prostate surgery and acute Urine Retention are detected in 5.9% of control group and 8.3% of study group during 10-year follow up. Compared with the control group, there was increase in the risk of prostate surgery and acute Urine Retention in the study group (HR = 1.83, 95% CI: 1.16 to 2.91) after adjusting for age, comorbidities, geographic region and socioeconomic status. Maximum Urine flow rate of less than 15ml/sec is a risk factor of urinary Retention and subsequent prostate surgery in BPH patients receiving alpha-1 blocker therapy. This result can provide a reference for clinicians.
Yu-hung Kuo - One of the best experts on this subject based on the ideXlab platform.
-
5-alpha-reductase inhibitor therapy postpones Urine Retention and prostate surgery in patients with prostate enlargement and a maximum uroflow rate of less than 15 ml/sec.
PloS one, 2017Co-Authors: Wenhsu Lin, Yu-hung Kuo, Shang-sen Lee, Tengfu HsiehAbstract:Background This study investigated the risk of transurethral resection of prostate (TURP) and acute Urine Retention (AUR) in relation to 5-alpha-reductase inhibitor (5ARI) therapy. Methods We identified 22,687 patients who were newly diagnosed with PE and low urinary tract symptoms (LUTS) between January 1, 2002 and December 31, 2011. We further classified study subjects who had moderate to severe LUTS and a maximum uroflow rate of less than 15ml/sec into three groups by their defined daily dose (DDD) of 5ARI used. The control group consisted of 7-28 cumulative DDD (cDDD) 5ARI users, while the short-term treatment group was 29-179cDDD 5ARI users, and the long-term treatment group was users of more than 180cDDD 5ARI. Each patient was monitored to identify those who subsequently developed TURP and AUR. Results TURP and AUR are detected in 5.6% of control group, 7.6% of short-term treatment group and 5.5% of long-term treatment group during 10-year follow up. Compared with the control group, there was no difference in the risk of TURP and AUR in the short-term and long-term treatment groups (HR = 1.41, 95% CI 0.76 to 2.62 and HR = 0.81, 95% CI 0.42 to 1.56, respectively). Conclusion 5ARI therapy did not change the risk of TURP and AUR events in patients with PE, moderate to severe LUTS and a maximum uroflow rate of less than 15 ml/sec in 10 years of follow-up. But long-term 5ARI used can postpone AUR and TURP for 8.16 months.
-
Maximum Urine Flow Rate of Less than 15ml/Sec Increasing Risk of Urine Retention and Prostate Surgery among Patients with Alpha-1 Blockers: A 10-Year Follow Up Study.
PloS one, 2016Co-Authors: Hsin-ho Liu, Tsunghsun Tsai, Shang-sen Lee, Yu-hung Kuo, Tengfu HsiehAbstract:The aim of this study was to determine the subsequent risk of acute Urine Retention and prostate surgery in patients receiving alpha-1 blockers treatment and having a maximum urinary flow rate of less than 15ml/sec. We identified patients who were diagnosed with benign prostate hyperplasia (BPH) and had a maximum uroflow rate of less than 15ml/sec between 1 January, 2002 to 31 December, 2011 from Taiwan's National Health Insurance Research Database into study group (n = 303). The control cohort included four BPH/LUTS patients without 5ARI used for each study group, randomly selected from the same dataset (n = 1,212). Each patient was monitored to identify those who subsequently developed prostate surgery and acute Urine Retention. Prostate surgery and acute Urine Retention are detected in 5.9% of control group and 8.3% of study group during 10-year follow up. Compared with the control group, there was increase in the risk of prostate surgery and acute Urine Retention in the study group (HR = 1.83, 95% CI: 1.16 to 2.91) after adjusting for age, comorbidities, geographic region and socioeconomic status. Maximum Urine flow rate of less than 15ml/sec is a risk factor of urinary Retention and subsequent prostate surgery in BPH patients receiving alpha-1 blocker therapy. This result can provide a reference for clinicians.
Li Chen - One of the best experts on this subject based on the ideXlab platform.
-
Analysis on therapeutic efect of TVT-O for female stress urinary incontinence(Report of 33 cases)
Journal of Xinjiang Medical University, 2009Co-Authors: Li ChenAbstract:Objective:To observe the operation effect of tension-free vaginal tape-obturator(TVT-O) for the female stress urinary in continence(FSUI).Methods:Thirty one patients with FSUI were treated with TVT-O operation,all the patients were confirmed to have stable bladder without outlet obstruction via clinical routine and urodynamic examination before operation.Results:All the patients were followed-up 6～24 months,30 cases were cured and the clinical symptoms disappeared after operation.Two patients with postoperative Urine Retention,after urethra dilated,the Urine Retention disappeared and no incontinence recurred.Urgent uracratia appeared on 1 cases,the symptom relieved after taking tolterodine L-tartrate. Conclusion:TVT-O is a simple,reliable,miniinvasive surgery to treat FSUI and with few complications.
